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Background: Given the large number of publications in all fields of practice, it is essential that clinicians focus on
the resources that provide the highest level of evidence (LOE). We sought to determine the LOE that exists in the
field of pediatrics, present in the general pediatric as well as high impact clinical literature.
Methods: Clinical pediatric literature, published between April 2011 and March 2012 inclusive in high-impact
clinical journals (HICJ) (New England Journal of Medicine, Journal of the American Medical Association, & The Lancet)
and the highest-impact general pediatric journals (GPJ) (Pediatrics, Journal of Pediatrics, & Archives of Pediatrics &
Adolescent Medicine), was assessed. In addition to the LOE, articles were evaluated on criteria including subspecialty
within pediatrics, number of authors, number of centers, and other parameters. Eligible level I randomized control
trials were appraised using the Consolidated Standards of Reporting Trials (CONSORT) guidelines.
Results: Of 6511 articles screened, 804 met inclusion criteria (68 in HICJ and 736 in GPJ). On average, LOE in
pediatrics-focused articles within The Lancet were significantly higher than all GPJ (p < 0.05). Average CONSORT
scores were significantly higher in HICJ vs. GPJ (15.2 vs. 13.6, respectively, p < 0.001).
Conclusions: LOE and quality of randomized control trials within the pediatric field is highest within HICJ, however,
only represent a small proportion of data published. Following CONSORT criteria, and promoting studies of high LOE
may allow authors and readers to turn to journals and articles of greater clinical impact.
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Evidence-based medicine purports to critically assess
and utilize high-quality studies to help guide clinical
practice. As the use of evidence-based medicine becomes
increasingly popular both in and outside the academic
sphere, supporting clinical practice with evidence-based
decisions in the field of pediatrics is an important and
evolving tenet of practice. At present, however, the
quantity of literature published in pediatric medicine is vo-
luminous, as it is in other medical fields. Clinicians do not
often have the time to critically appraise and assess all
relevant publications, and miss out on high-quality, rele-
vant studies due to readership. Aside from selecting arti-
cles from ‘reputable journals’ , no easily accessible and
comprehensive screen is available for clinicians to help
them decide which publications present studies of sound* Correspondence: jacobson.dustin@gmail.com
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unless otherwise stated.methodology and high level of evidence (LOE). Three
other studies have done similar work in the fields of
pediatric orthopedic surgery, neurosurgery and plastic sur-
gery [1-3]. Namely, these works have suggested that higher
levels of evidence and greater degrees of transparency in
reporting for randomized control trials (RCTs) exist in
higher impact clinical journals.
The objective of the current study is to determine the
LOE that currently exists in the field of pediatrics.
Specifically, this study compares the LOE of pediatric-
related clinical studies found in general pediatric journals
(GPJ) to that found in high impact clinical journals (HICJ)
using the Oxford LOE guidelines, whereby the highest
LOE includes RCTs and the lowest LOE includes studies
that detail expert opinion/case series. Moreover, we com-
pare randomized control trial design between these two
groups.
We hypothesized that HICJ would have higher (closer to
level I) mean LOE and higher CONSORT ratings (moreral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jacobson et al. BMC Pediatrics  (2015) 15:3 Page 2 of 7fulfilled criteria), compared to GPJ. CONSORT criteria re-
late to study design and reporting of more criteria relate
to better and higher quality RCTs [4-6].
Methods
Data sources and search methods/strategy
Journals with the highest impact factors in the English
language, as reported by Thomas Reuters Journal
Citation Reports, were chosen [7]. This study was de-
signed to focus on clinically-oriented research; as such,
journals emphasizing or exclusively publishing research
from the basic sciences were excluded from this para-
digm. General pediatric journals selected for review in-
cluded Pediatrics, Journal of Pediatrics (JofP), and
Archives of Pediatrics & Adolescent Medicine (APAM),
as these journals represent the highest impact GPJ. In
addition, general medical journals with total cite counts
under 100,000 in the previous year were excluded to
help ensure that journals reviewed would be of wide-
spread appeal. Namely, journals excluded because of
basic science output include Nature and Science and
subspecialty journals were excluded to ensure
generalizability. After this exclusion process, the three
journals with the highest impact factors and highest cite
counts were selected for review: New England Journal of
Medicine (NEJM), The Lancet and Journal of the
American Medical Association (JAMA).
Inclusion and exclusion criteria
Studies screened included clinical papers that were hu-
man studies with a case series, case-control, cohort or
RCT/metanalysis design. These studies had a focus in
pediatrics and were published in English. We excluded
non-English articles, basic science or cadaver studies,
case reports, review articles of non-clinical cases and ex-
pert opinions without clinical examples. Study abstracts
were assessed for initial eligibility (i.e. included if
pediatric-focused). Once extracted, two reviewers
assessed eligibility independently by hand searches of
journal articles (DJ & KB); they were blinded to the
other’s allocation. Discrepancies were discussed between
reviewers to achieve consensus. Interobserver reliability
was very good (kappa scores (κ) > 0.8).
Data extraction and synthesis
Articles published between April 2011 and March 2012
were screened and categorized on the basis of journal,
date of publication, subspecialty within pediatrics, num-
ber of authors, geographic region of corresponding
author, number of centers used in trial, number of
subjects/trials (latter used in meta-analyses), minimum
age of entry of subjects, average age of entry of subjects,
study subtype and LOE. In addition, the quality of report-
ing of eligible level I RCTs were appraised using theConsolidated Standards of Reporting Trials (CONSORT)
guidelines [8]. Each eligible and included article was evalu-
ated by two reviewers (DJ and KB). LOE allocation was
completed using the Centre for Evidence Based Medicine’s
Oxford Level of Evidence Guidelines, grouping subclasses
within each LOE category (i.e. Ia, Ib, Ic become level I)
[9]. In brief, higher level of evidence is closer to level I
evidence (i.e. RCT is level I) and lower level of evidence is
closer to level V evidence (i.e. expert opinion is level V).
Reviewers were blinded to LOE allocation as well as
CONSORT grading. Once the analysis was completed, any
disagreements that occurred between reviewers were dis-
cussed until a consensus was reached.
Oxford LOE and CONSORT guidelines were used to
examine top GPJ, as well as HICJ. The Oxford LOE
guidelines are widely known and have been used effect-
ively with individuals not trained in epidemiology with
excellent interobserver reliability [3]. Likewise, the
CONSORT guidelines represent the most widely used
and accepted system for assessing RCTs, for their trans-
parency of reporting [10].Statistical analysis
Data was collected using spreadsheets and imported for
analyzed using SPSS 20.0 statistical software (IBM Corp,
Armonk, NY). We used descriptive statistics to compare
LOE between journals during the entire time period
from April 2011 to March 2012. We compared the levels
of evidence independently and grouped into high (Levels
I and II) and low (Levels III and IV) using chi-square
and students t-tests. Mean differences in LOE between
journals was analyzed using one-way ANOVAs with
Bonferroni post-hoc comparisons. We conducted a logis-
tic regression analysis to determine the factors associated
with higher or lower levels of evidence in the literature.
All tests were one-tailed with a p value of <0.05 used as
the conventional level of significance. To be sufficiently
powered (i.e. beta = 0.20, alpha = 0.05, 80% study
power) to identify a 0.5 absolute difference in mean
LOE between high- and low-impact journals we re-
quired a total of 68 studies in each group. This is, in-
deed, an arbitrary cut-off. Because of the abstract
nature of level of evidence being a numerical categor-
ical variable, the conversion to an integer value for the
purpose of comparisons of means has been done to aid
in analysis and interpretation. There is support in the
published literature for this type of interpretation and a
mean difference of 0.5 being a useful cut-off [1,2].Ethics
No ethics approval was sought for this study or required
by our research ethics board.





Journal Number of Authors
JAMA 24 (3.0) <3 17 (2.1)
Lancet 27 (3.4) 3 89 (11.1)
NEJM 17 (2.1) 4 116 (14.4)
APAM 103 (12.8) 5 108 (13.4)
J. Peds 256 (31.8) 6 125 (15.5)
Peds 377 (46.9) 7 100 (12.4)
>7 249 (31.0)
Study type
Therapeutic 331 (41.2) Number of Centers**
Prognostic 403 (50.1) 1 605 (75.4)
Diagnostic 58 (7.2) 2 37 (4.6)
Economic & Decision
Analysis
12 (1.5) 3 23 (2.9)
4 15 (1.9)
Number of subjects* 5 10 (1.2)
<10 31 (3.9) >5 112 (14.0)
11-50 109 (13.6)
51-100 91 (11.3) Sub-Specialty
101-500 237 (29.6) Adolescent Medicine 36 (4.5)
501-1,000 60 (7.5) Pediatric Cardiology 47 (5.8)
1,001-5,000 131 (16.3) Allergy & Immunology 39 (4.9)
5,001-10,000 38 (4.7) Clinical Pharmacology 9 (1.1)
10,001-50,000 62 (7.7) Pediatric Critical Care 17 (2.1)
50,001-100,000 9 (1.1) Developmental
Pediatrics
69 (8.6)




Region Gastroenterology 28 (3.5)
North America 529 (65.8) Hematology/
Oncology
13 (1.6)
South America 7 (0.9) Infectious Disease 67 (8.3)
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Literature search
Six thousand five hundred and eleven articles were
screened, of which eight hundred and four papers met
inclusion criteria (Figure 1). Twenty four articles (3.0%)
were found in JAMA, twenty seven (3.4%) were found in
The Lancet, seventeen (2.1%) were found in NEJM, one
hundred and three (12.8%) were found in APAM, two
hundred and fifty six (31.8%) were found in JofP, and
three hundred and seventy seven (46.9%) were found in
Pediatrics (Table 1).
Study characteristics
The majority of studies were pertinent to general
pediatrics and the medical subspecialties (86.6%) with
only a small minority related to pediatric surgery (all
types) (3.7%) or emergency medicine (2.4%) (Table 1).
Most articles originated from North America (65.8%) or
Europe (21.6%). Studies from a single center (75.4%)
were most common amongst those assessed, followed by
multi-center studies with greater than five centers in-
volved (14.0%). Level I studies had significantly more au-
thors than level II studies (p = 0.001) or level IV studies
(p = 0.009), but not significantly greater than level III
studies (p = 0.098). Otherwise, no significance (p > 0.05)
was found with all other study parameters in relation to
the LOE.
Level of evidence
Of 804 articles, 204 (25.4%) were graded level I, 175
(21.8%) were graded level II, 93 (11.6%) were graded level
III, and 322 (41.3%) were graded level IV. Proportions of
higher (LOE I and II) to lower (LOE III and IV) levels of
evidence were calculated for each journal, as well as
grouped proportions based on high impact vs. general
pediatric literature. The highest ratio of high-to-low LOE
was in The Lancet (3.5) followed by NEJM (2.4) with JAMA
(1.0) and the GPJ journals having much lower ratios (Table 2
and Figure 2). Mean LOE by journal categories, as well
as grouped based on HICJ and GPJ, show that LOE inFigure 1 Study flow diagram.
Europe 174 (21.6) Neonatal/Perinatal
Medicine
68 (8.5)
Asia 29 (3.6) Nephrology 13 (1.6)
Middle East 18 (2.2) Neurology 35 (4.4)
India 2 (0.2) Respirology 57 (7.1)
Africa 6 (0.7) Rheumatology 8 (1.0)
Australia 39 (4.9) Surgery 30 (3.7)
General Pediatrics 141 (17.5)
Other 58 (7.2)
*Number of subjects not reported in 2 studies, **Number of centers not
reported in 2 studies.
JAMA – Journal of the American Medical Association, NEJM – New England
Journal of Medicine, APAM – Archives of Pediatrics and Adolescent Medicine,
J. Peds – Journal of Pediatrics, Peds – Pediatrics.
Table 2 Level of evidence by proportion and mean level of evidence based on journal
Journal JAMA Lancet NEJM APAM J. Peds Peds Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Level of evidence
I 8 (33.3) 16 (59.3❖) 10 (58.8‡) 26 (25.2◆) 63 (24.6◆,f) 81 (21.5◆,f) 204 (25.4)
II 4 (16.7) 5 (18.5) 2 (11.8) 21 (20.4) 55 (21.5) 88 (23.3) 175 (21.8)
III 5 (20.8) 3 (11.1) 3 (17.6) 9 (8.7) 25 (9.8) 48 (12.7) 93 (11.6)
IV 7 (29.2) 3 (11.1◆) 2 (11.8) 47 (45.6❖) 113 (44.1❖) 160 (42.4❖) 332 (41.3)
Ratio LOE I-II:III-IV 1.00 3.50 2.40 0.84 0.86 0.81 0.89
Mean LOE 2.46 1.74† 1.82∫ 2.75* 2.73*,§ 2.76*,§ 2.69
❖Higher proportion compared to ◆(p < 0.05), ‡ Higher proportion compared to ƒ(p < 0.05).
†Higher LOE compared to *(p < 0.01), ∫ Higher LOE compared to §(p < 0.05).
JAMA – Journal of the American Medical Association, NEJM – New England Journal of Medicine, APAM – Archives of Pediatrics and Adolescent Medicine, J. Peds – Journal
of Pediatrics, Peds – Pediatrics, LOE – Level of Evidence.
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evidence) compared to all GPJ (JoP p = 0.001, APAM
p = 0.002, Pediatrics p = 0.0001). NEJM had signifi-
cantly higher LOE compared to Pediatrics (p = 0.027)
and JofP (p = 0.039); however, it was not significantly
higher than the average LOE found in APAM (p = 0.051).
JAMA did not differ significantly in evidence compared to
all other journals (JoP p = 0.255, APAM p = 0.261,
Pediatrics p = 0.215, Lancet p = 0.657, NEJM p = 0.106).
The Lancet and NEJM had higher proportions of level I
& II evidence compared to all other journals (Lancet vs
JAMA p = 0.02, APAM p = 0.0005, JoP p = 0.001, Pediatrics
p = 0.003; NEJM vs JAMA p = 0.004, APAM p = 0.0007,
JoP p = 0.0001, Pediatrics p = 0.0004) but did not differ sig-
nificantly between each other (p = 0.47). As well, The
Lancet was found to have significantly higher proportionsFigure 2 Level of evidence (LOE) ratios by journal and category (highof level I evidence compared to all GPJ (p = 0.03), and sig-
nificantly lower proportions of level IV evidence compared
to all GPJ (p = 0.02) (Table 2). This same result was not
found with any other HICJ. When comparing grouped
HICJ to GPJ, the proportion of level I evidence was signifi-
cantly higher in HICJ (p = 0.002) (Table 3). Additionally,
level IV evidence was lower in HICJ compared to GPJ
(p = 0.03). Reliability in assessing kappa levels for LOE
between the two reviewers measured 0.88.
CONSORT grading
Although no significant differences in quality of report-
ing were found across journals in CONSORT checklist,
average CONSORT scores were significantly higher in
the grouped HICJ compared to GPJ (15.2 vs. 13.6, re-
spectively, p = 0.001). Proportions of articles based onimpact & low impact).
Table 3 Level of evidence and mean level of evidence based on journal type (i.e. high impact factor clinical journals vs.
low impact factor general pediatric journals)
Journal General clinic journals Pediatric-specific journals Total
n (%) n (%) n (%)
Level of evidence
I 34 (50.0)* 170 (23.1)* 204 (25.4)
II 11 (16.2) 164 (22.3) 175 (21.8)
III 11 (16.2) 82 (11.1) 93 (11.6)
IV 12 (17.6)* 320 (43.5)* 332 (41.3)
Ratio LOE I-II:III-IV 1.96 0.83 0.89
Mean LOE 2.01† 2.75† 2.69
*p < 0.05, †p < 0.01.
LOE – Level of Evidence.
Mean LOE – closer to 1 indicates RCT level and closer to 5 indicates expert opinion level.
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can be found in Figure 3. Reliability in assessing kappa
levels for CONSORT grading between the two reviewers
measured 0.89.
Discussion
This study demonstrates that studies with a higher LOE
are more likely to be found in HICJ as opposed to GPJ.
It is unclear why the HICJ differed in their LOE. One
retrospective hypothesis was that researchers would
preferentially submit higher LOE articles to journals
with higher impact factors (i.e. NEJM and The Lancet),
however, The Lancet seemed to have a trend towardsFigure 3 CONSORT grading of articles based on journal type and totahighest LOE even compared to NEJM. It is still unclear
why this difference is seen. It is possible that the differ-
ence relates to editorial differences between these and
other journals. What is clear is that lower LOE exists in
GPJ. The researchers in this study believe this is due to
this aforementioned submission bias whereby authors
are incentivized to submit and publish in HICJ. How-
ever, with such few studies published in HICJ, it is clear
that the majority of information in terms of shear num-
bers used for evidence-based practice comes from GPJ.
Therefore, it is crucial to encourage the submission and
publication of good quality LOE and RCTs to GPJ. More-
over, while the minority of pediatric articles are publishedl CONSORT score (out of 17).
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enced, and incorporated into practice.
RCT allocation used a subset of CONSORT guideline
statements, chosen by the CONSORT Group to repre-
sent the minimum characteristics needed in reporting
RCTs [8]. While reviewers did look at all aspects of the
full article, the decision was made to use a subset of
CONSORT criteria that examined what the CONSORT
group and these researcher’s thought were the most im-
portant measures. Namely, these are measures that are
easily identified by the reading public, and more import-
antly, a subset of minimum guidelines that the CONSORT
group has identified for use in quickly and efficiently
assessing transparency in reporting. It is well established
that RCTs are at risk of bias and with this well-established
and validated tool, although lower attributable bias
cannot be guaranteed with its use, foreseeable risks are
addressed [11]. Journals that implement these guide-
lines in their manuscript assessment process report
higher quality RCTs [4-6].
When one looks only at the RCTs found in this ana-
lysis with the CONSORT criteria applied a similar trend
to LOE is found. When grouped into GPJ and HICJ,
HICJ have significantly higher fulfilled CONSORT cri-
teria as compared to GPJ. These findings are consistent
with findings by DeMauro et al. that in neonatal/infant
subset populations of the pediatric population, quality of
RCTs were higher in HICJ as compared to GPJ [12].
Looking at secondary characteristics, a trend of
higher LOE based on increasing number of authors was
noted. No significance was observed between the publi-
cation groups for subspecialty within pediatrics, geo-
graphic region of corresponding author, number of
centers, number of subjects/trials, minimum age of
entry of subjects, and average age of entry of subjects.
Interestingly, the number of centers/subjects was not a
predictor of high LOE. Additionally, age of entry of
subjects and/or average age of subjects in trials did not
correlate with LOE/CONSORT grading. This suggests
that age is not a hindrance in designing and approving
sound studies. As such, with a clearly demonstrated
need for high-quality research in these ages [13,14], this
finding negates excuses for poor methodology. This is
not to say that research in children is not without limi-
tations; with less prevalence of childhood disease [15]
and smaller amounts of therapeutic agents designed for
use in children [16], enrollment remains a challenge.
Our analyses suggest that better evidence is found in
HICJ, but little is known regarding readership by pedia-
tricians and other health care professionals. Therefore,
although low in number, in order to not miss out on
quality research, HICJ should be incorporated into the
reference repertoire of practicing pediatricians and other
health care professionals.Our study has several limitations. First, it should be
noted that our data does not allow for comment on any
study-type excluded in our original search (i.e. basic
science study) as LOE only applies to clinical studies.
Additionally, neither our data nor our Oxford measuring
tool discriminated between subdivisions within LOE (i.e.
level Ia vs. Ib). This distinction within grades was not
made in order to limit analysis to what would be consid-
ered realistic differences between LOE. However, our
inter-observer agreement for both LOE and CONSORT
were excellent (kappa scores (κ) > 0.8). This study should
not imply that poor quality research is published in GPJ,
rather, the comparison is important. Finally, our search
and analysis was limited to a small subset of HICJ and GPJ.
Therefore, further research may be needed to compare
these two groups of literature outside of the clinical LOE.
Conclusions
HICJ like The Lancet publish high LOE and well designed
RCTs, however publish only a fraction of the amount of
literature published by GPJ. Therefore, although important
to incorporate HICJ into clinical repertoire, the vast ma-
jority of work published in GPJ should not be overlooked.
Instead, raising LOE and RCT quality of all published
work is the goal. Future research may look more at sub-
mission biases in favor of high impact medical journals.
Since the introduction of evidence-based medicine, ef-
forts have been made to publish the highest quality
research in publications considered to be at the pinnacle
of their fields. By analyzing the most common journals
in the field, this work more effectively addresses one of
the basic pillars in medicine; being a lifelong learner and
adapting one’s practice of medicine based on evolving
knowledge and evidence.
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